Literature DB >> 32413038

Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations.

Elsa Hansen1, Jason Karslake2, Robert J Woods3, Andrew F Read4, Kevin B Wood2,5.   

Abstract

Standard infectious disease practice calls for aggressive drug treatment that rapidly eliminates the pathogen population before resistance can emerge. When resistance is absent, this elimination strategy can lead to complete cure. However, when resistance is already present, removing drug-sensitive cells as quickly as possible removes competitive barriers that may slow the growth of resistant cells. In contrast to the elimination strategy, a containment strategy aims to maintain the maximum tolerable number of pathogens, exploiting competitive suppression to achieve chronic control. Here, we combine in vitro experiments in computer-controlled bioreactors with mathematical modeling to investigate whether containment strategies can delay failure of antibiotic treatment regimens. To do so, we measured the "escape time" required for drug-resistant Escherichia coli populations to eclipse a threshold density maintained by adaptive antibiotic dosing. Populations containing only resistant cells rapidly escape the threshold density, but we found that matched resistant populations that also contain the maximum possible number of sensitive cells could be contained for significantly longer. The increase in escape time occurs only when the threshold density-the acceptable bacterial burden-is sufficiently high, an effect that mathematical models attribute to increased competition. The findings provide decisive experimental confirmation that maintaining the maximum number of sensitive cells can be used to contain resistance when the size of the population is sufficiently large.

Entities:  

Year:  2020        PMID: 32413038     DOI: 10.1371/journal.pbio.3000713

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   8.029


  8 in total

1.  Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations.

Authors:  Sergey V Melnikov; David L Stevens; Xian Fu; Hui Si Kwok; Jin-Tao Zhang; Yue Shen; Jeffery Sabina; Kevin Lee; Harry Lee; Dieter Söll
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-13       Impact factor: 11.205

2.  Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.

Authors:  Maximilian A R Strobl; Jill Gallaher; Jeffrey West; Mark Robertson-Tessi; Philip K Maini; Alexander R A Anderson
Journal:  Commun Med (Lond)       Date:  2022-04-25

3.  Price equation captures the role of drug interactions and collateral effects in the evolution of multidrug resistance.

Authors:  Erida Gjini; Kevin B Wood
Journal:  Elife       Date:  2021-07-22       Impact factor: 8.140

Review 4.  Modeling transmission of pathogens in healthcare settings.

Authors:  Anna Stachel; Lindsay T Keegan; Seth Blumberg
Journal:  Curr Opin Infect Dis       Date:  2021-08-01       Impact factor: 4.968

5.  Fighting microbial pathogens by integrating host ecosystem interactions and evolution.

Authors:  Alita R Burmeister; Elsa Hansen; Jessica J Cunningham; E Hesper Rego; Paul E Turner; Joshua S Weitz; Michael E Hochberg
Journal:  Bioessays       Date:  2020-12-30       Impact factor: 4.653

6.  Ethics and antibiotic resistance.

Authors:  Euzebiusz Jamrozik; George S Heriot
Journal:  Br Med Bull       Date:  2022-03-21       Impact factor: 5.841

7.  Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.

Authors:  Jessica Cunningham; Frank Thuijsman; Ralf Peeters; Yannick Viossat; Joel Brown; Robert Gatenby; Kateřina Staňková
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

8.  Drug-induced resistance evolution necessitates less aggressive treatment.

Authors:  Teemu Kuosmanen; Johannes Cairns; Robert Noble; Niko Beerenwinkel; Tommi Mononen; Ville Mustonen
Journal:  PLoS Comput Biol       Date:  2021-09-23       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.